Form 4: Imunon Inc. Insider Trading Activity

Susan Eylward, General Counsel and Corp Sec of Imunon, Inc., reported transactions involving common stock, including stock granted in lieu of salary.

Summary

• Susan Eylward, General Counsel and Corporate Secretary of Imunon, Inc., reported transactions on July 2, 2026, and July 6, 2026.
• On July 2, 2026, 920 shares of common stock were acquired at a price of $1.91 per share, with the transaction code 'A' indicating acquisition.
• This acquisition was described as stock granted in lieu of cash for a portion of base salary.
• Following this acquisition, Eylward beneficially owned 3,816 shares of common stock directly.
• On July 6, 2026, 920 shares of common stock were disposed of at a price of $1.88 per share, with the transaction code 'S' indicating a sale.
• Following this disposition, Eylward beneficially owned 2,896 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, reflecting routine insider transactions including compensation-related stock grants and a subsequent sale, without strong indicators of positive or negative sentiment towards the company's future.

Positives

• Susan Eylward received stock as compensation, indicating a form of equity-based incentive or payment for services rendered.
• The acquisition of stock at $1.91 per share suggests a valuation for the company's equity at that time.

Negatives

• Susan Eylward sold 920 shares of common stock shortly after acquiring them, at a slightly lower price ($1.88 per share).

Future Outlook

This filing does not contain forward-looking statements or guidance.

Management Comments

• Stock granted in lieu of cash for portion of base salary.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into executive and director trading activities. These filings are crucial for investors seeking to understand management's confidence in the company's prospects.

Stakeholder Impact

• Shareholders: Gain insight into insider trading activity, which can influence perceptions of management confidence.
• Employees: The stock grant indicates a form of compensation for executives.
• Creditors: No direct impact indicated by this filing.

Key Dates

Keywords

Form 4, Insider Trading, SEC Filing, Imunon Inc., IMNN, Common Stock, Beneficial Ownership, Stock Compensation, Executive Transactions